Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HCB-MNCs for Refractory Diabetic Foot
NCT05999656Unknown
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- May 2023
- Primary completion
- May 2024
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of umbilical cord blood mononuclear cells in diabetic foot disease (DFD), sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: Number of patients with no adverse reactions at 24 weeks and Rate of wound area change at 24 weeks. Status: unknown.
02
Drugs
umbilical cord blood mononuclear cells
03
Conditions
diabetic foot disease (DFD)
Beyond the preview
Go deeper on NCT05999656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05999656.